Long-term results of autologous scaffold-free tissue-engineered vascular graft for hemodialysis access
The Journal of Vascular Access · 2024-01 · 25 (1) · 254-264
DOI: 10.1177/11297298221095994 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Vascular Access, online erschienen am 30.06.2022. Verfasst von Wojciech Wystrychowski und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of General, Vascular and Transplant Surgery, Medical University of Silesia, Katowice, Poland. Hauptthemen laut MEDLINE: Arteriovenous Shunt, Surgical, Kidney Failure, Chronic. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Cytograft Tissue Engineering.
Abstract (Originalsprache)
Background
The growing size of the end stage renal disease (ESRD) population highlights the need for effective dialysis access. Exhausted native vascular access options have led to increased use of catheters and prosthetic shunts, which are both associated with high risks of access failure and infection. Emerging alternatives include tissue-engineered vascular grafts (TEVG). Here we present the endpoint results for 10 ESRD patients with the scaffold-free tissue-engineered vascular access produced from sheets of extracellular matrix produced in vitro by human cells in culture.
Methods
Grafts were implanted as arteriovenous shunts in 10 ESRD patients with a complex history of access failure. Follow-up included ultrasound control of graft morphology and function, dialysis efficiency, access failure, intervention rate, as well as immunohistochemical analysis of graft structure.
Results
One patient died of unrelated causes and three shunts failed to become useable access grafts during the 3-month maturation phase. The 12-month primary and secondary patency for the other six shunts was 86%. Survival of six shunts functioning as the vascular access was 22 ± 12 months with longest primary patency of 38.6 months. The dialysis event rate of 3.34 per patient-year decreased significantly with the use of this TEVG to 0.67.
Conclusions
This living autologous tissue-engineered vascular graft seems to be an alternative to synthetic vascular access options, exhibiting advantages of native arteriovenous fistula.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of General, Vascular and Transplant Surgery, Medical University of Silesia, Katowice, Poland.
- Instituto Argentino de Diagnóstico y Tratamiento, Buenos Aires, Argentina.
- Cytograft Tissue Engineering, Novato, CA, USA.
- University of Bordeaux, INSERM, BIOTIS, Bordeaux, France.
- Fresenius Dialysis Center Hospital Alemán, Buenos Aires, Argentina.
- Fresenius Dialysis Center, Tychy, Poland.
ORCID-Profile: Wojciech Wystrychowski
Förderung
- Cytograft Tissue Engineering
Zitieren
APA
Wystrychowski, W., Garrido, S. A., Marini, A., Dusserre, N., Radochonski, S., Zagalski, K., Antonelli, J., Canalis, M., Sammartino, A., Darocha, Z., Baczyński, R., Cierniak, T., Regele, H., de la Fuente, L. M., Cierpka, L., McAllister, T. N., & L'Heureux, N. (2024). Long-term results of autologous scaffold-free tissue-engineered vascular graft for hemodialysis access. The Journal of Vascular Access, 25(1), 254-264. https://doi.org/10.1177/11297298221095994
Vancouver
Wystrychowski W, Garrido SA, Marini A, Dusserre N, Radochonski S, Zagalski K, et al. Long-term results of autologous scaffold-free tissue-engineered vascular graft for hemodialysis access. The Journal of Vascular Access. 2024;25(1):254-264. doi:10.1177/11297298221095994
BibTeX
@article{Wystrychowski2024,
author = {Wystrychowski, Wojciech and Garrido, Sergio A and Marini, Alicia and Dusserre, Nathalie and Radochonski, Sam and Zagalski, Krzysztof and Antonelli, Jorge and Canalis, Manuel and Sammartino, Andrea and Darocha, Zbigniew and Baczyński, Ryszard and Cierniak, Tomasz and Regele, Heinz and de la Fuente, Luis M and Cierpka, Lech and McAllister, Todd N and L'Heureux, Nicolas},
title = {Long-term results of autologous scaffold-free tissue-engineered vascular graft for hemodialysis access},
journal = {The Journal of Vascular Access},
year = {2024},
volume = {25},
number = {1},
pages = {254--264},
doi = {10.1177/11297298221095994}
}
EUVIMED